Join
Live feed
·
PRReleasevia Quantisnow
Arcutis Biotherapeutics Inc. logo

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

ByQuantisnow·Wall Street's wire, on your screen.
ARQT· Arcutis Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARQT (Arcutis Biotherapeutics Inc.) and more on Quantisnow.